bluuebunny/crossref_metadata_2025_split huggingface dataset:
792-P: Evaluation of Long-Term Glycemic Outcomes by Ethnicity in Adults with Type 1 Diabetes Using Control-IQ Technology
Authors: GRAHAM RISHI , SINGH HARSIMRAN , MUELLER LARS , MANNING MICHELLE L. , ALENCAR GABRIEL , WHITE KIRSTIN N. , WHEATCROFT ALEX , CARMELO KAREN , KATCHALSKI RAVID , ARONOFFSPENCER ELIAH S. , PINSKER JORDAN E. , HABIF STEPHANIE 
Published: May 2022

Despite increasing prevalence of T1D in ethnic minorities, they remain underrepresented in research studies evaluating diabetes technologies. Experiences of diverse cohorts are essential to assessing acceptability of diabetes devices. The Control-IQ Observational (CLIO) Study is an ongoing prospective, real-world evaluation of the Tandem Diabetes Care t:slim X2 insulin pump with Control-IQ technology in diverse people with T1D. We evaluated glycemic metrics from adults completing the 12-month CLIO study. Participants with ≥75% overall CGM use during this time were included in the analysis. Outcomes were analyzed using a Wilcoxon test. Sample included 1,045 adults (921 Whites, 74 Hispanics, 34 Blacks, 16 Asians) with Black participants reporting the highest baseline HbA1c (median=8% [IQR=7-8.6)) . Glucose Management Indicator (GMI) at study end reflected glycemic improvements for participants with Blacks showing a clinically relevant 0.7% overall reduction (7.3% [6.9-7.6]) (p&lt;0.001) (Figure 1) . Overall, sensor time in range (TIR) at 12 months ranged from 64.9% [56.8-70.5] for Black participants to 72.6% [62.8-80.8] for the White cohort. These findings confirm long-term successful use of Control-IQ technology across diverse ethnicities. Further evaluation of glycemic disparities is recommended to help inform patient support systems.

Disclosure
R.Graham: Research Support; Tandem Diabetes Care, Inc. E.S.Aronoffspencer: Research Support; Tandem Diabetes Care, Inc. J.E.Pinsker: Employee; Tandem Diabetes Care, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. S.Habif: Employee; Tandem Diabetes Care, Inc. H.Singh: Employee; Tandem Diabetes Care, Inc. L.Mueller: Employee; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Stock/Shareholder; Tandem Diabetes Care, Inc. M.L.Manning: Employee; Tandem Diabetes Care, Inc. G.Alencar: Employee; Tandem Diabetes Care, Inc. K.N.White: Employee; Tandem Diabetes Care, Inc. A.Wheatcroft: Employee; Tandem Diabetes Care, Inc. K.Carmelo: None. R.Katchalski: Employee; Tandem Diabetes Care, Inc.

Funding
Tandem Diabetes Care
800-P: Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Adults with Type 1 Diabetes
Authors: AMUEDO SANDRA , ANTEQUERA MARÍA , AZRIEL SHARONA 
Published: May 2022

Background and Aims: Members of the diabetes community have started developing their own Do-It-Yourself Artificial Pancreas Systems (DIY APS) , also known as Open-Source Automated Insulin Delivery (AID) Systems and use the online hashtag “#WeAreNotWaiting” to promote the development of it. DIY APS systems inclued OpenAPS, Loop and AndroidAPS. The aim of the study was to evaluate retrospectively glycemic outcomes with the use of DIY APS in adults with T1D.
Methods: Subjects with T1D started using open-source AID systems (AndroidAPS with Insight insulin pump and Dexcom G6 or FreeStyle Libre 2 CGM and Loop with Minimed Paradigm and Dexcom G6) . Glycemic outcomes at baseline on open-loop and after 12 months on DIY APS were compared including time in different glucose ranges, management indicator (GMI) , mean glucosa levels, glycemic variability and Patient Glycaemic Status (PGS) .
Results: Patients with T1D users open-source AID systems (22 AndroidAPS and 1 Loop) were included (age 38.4±years, 56.5% females, diabetes duration 20.8±10.6 years and capillary HbA1c 6.6±0.5%) . 18 patients previous insulin pump users with a use 3.5±4 years, 5 patients previously treated with multidose and CGM use 2.6±2.1 years. GMI decreased from 6,6±0.6% to 6±0.5% (p&lt;0.001) . At 12 months, time in range (TIR) 70-180 mg/dL increased from 69.9±11.5% at baseline to 87.5±7.8% (p&lt;0.001) , time in hyperglycemia &gt;180 and &gt;250 mg/dL were reduced from 23.5±11,5% to 9.6±7.5% and from 5.1% (2-9) to 0.6% (0-3) , respectively (p&lt;0.001) and time in hypoglycemia &lt;70 and &lt;54 mg/dL decreased from 5±3.6% to 2.8±2.1% (p=0.006) and from 1.3±1.5% to 0.4±0.5% (p=0.014) . Improvements in glycemic variability from 35.7±6% to 30.3±6.2% (p=0.001) . At 12 months, PGS and sensor glucose were reduced from 54.4±36% to 23±19.6% and from 144.7±18.3% to 127±14% (p&lt;0.001) .
Conclusions: Open-source AID systems is safe and improved outcomes glycemic after 12 months of use in a real-world clinical setting in adults with T1D.

Disclosure
S.Amuedo: None. M.Antequera: None. S.Azriel: None.
844-P: Jatupalathika Extract Acts via G-Protein-Coupled Receptors to Stimulate GLP-1 Secretion in STC-1 Cell Line
Authors: CHAICHANA CHARTCHAI , KHUMKHANA NANTA , WONGSHAYA PAKWUAN , DEEKUM WANJAN , PRAMYOTHIN PORNPOJ 
Published: May 2022

One of the most important molecular targets for the prevention and treatment of diabetes is glucagon-like peptide-1 (GLP-1) , a molecule secreted by enteroendocrine L cells in the intestine. It has been reported that nutrients, as well as non-nutritional dietary factors, can activate GLP-1 secretion. Jatupalathika (JPT) is a traditional herbal formulation of four dried fruits: Terminalia bellirica (Gaertn.) Roxb., Terminalia chebula Retz., Terminalia arjuna (Roxb.) Wight & Arn., and Phyllanthus emblica Linn. JPT extracts have traditionally been used for their anti-oxidant, anti-aging, body fat depletion, and weight loss properties. However, its effects on glucose metabolism and GLP-1 are not known. Thus, we evaluated the antidiabetes potential of JPT aqueous extracts by assessing its ability to induce GLP-1 secretion in a mouse intestinal cell line (STC-1) . The MTT assay was used to assess the cytotoxicity, and the LUMINEX multiplex assays were used to assess GLP-1 hormone secretion. When compared to control, JPT extracts (125 µg/ml) increased GLP-1 secretion after 45-120 minutes of incubation without any effects on cell survival. The mechanism of action of GLP-1 secretion activity in cells was studied using real-time PCR. We discovered an increase in expression of six genes related to GLP-1 secretion: SLC5A1 (encoding SGLT1) , FFAR2 (encoding GPR43) , FFAR3 (encoding GPR41) , GPR119, GPBAR1, and CABP1. This finding demonstrated that JTP extract significantly increased GLP-1 hormone production via G-protein-coupled receptor activation, which also promotes Ca2+ release from the endoplasmic reticulum. Phytochemical profiling and molecular docking study revealed that Ellagic acid and Orientin are abundant metabolites with a favorable ability to bind the FFAR2/3 protein, acting as potential agents that aid in GLP-1 production. The findings showed that JPT might be useful in the prevention and treatment of diabetes. However, more research on in vivo effects is required.

Disclosure
C.Chaichana: None. N.Khumkhana: None. P.Wongshaya: None. W.Deekum: None. P.Pramyothin: Research Support; Novo Nordisk, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk.
859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV
Authors: SRIDHAR VIKAS S. , COSENTINO FRANCESCO , DAGOGO-JACK SAMUEL , PRATLEY RICHARD E. , FREDERICH ROBERT , ESSEX MARGARET N. , MALDONADO MARIO , LIU CHIH-CHIN , MANCUSO JAMES P. , CHERNEY DAVID 
Published: May 2022

The effect of ertugliflozin (ERTU) on serum uric acid (SUA) and gout-related outcomes in VERTIS CV (NCT01986881) was investigated. Patients with T2D and ASCVD were randomized to ERTU 5 mg (n=2752) , 15 mg (n=2747) (doses pooled for analyses) , placebo (PBO; n=2747) . Changes in SUA and composite of gout onset or initiation of anti-gout medication were assessed. LSM changes from baseline in SUA (mg/dL [95% CI]) at week 260 were −0. (−0.25, −0.13) and 0. (−0.02, 0.15) in the ERTU and PBO groups, respectively, nominal P&lt;0.0 (Fig. 1) . The HR (95% CI) for the composite of gout-related outcomes was 0.76 (0.580, 1.002) , nominal P=0.052 (Fig. 2) . Treatment with ERTU was associated with reductions from baseline in SUA and a non-significant reduction in gout-related outcome events compared with PBO.

Disclosure
V.S.Sridhar: None. D.Cherney: Other Relationship; AbbVie Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Research & Development, LLC, Lilly, Maze, BMS, CSL-Behring, Merck, Otsuka, Novartis and Novo-Nordisk , Mitsubishi Tanabe Pharma Corporation, Sanofi, Research Support; Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca and Novo-Nordisk. F.Cosentino: Advisory Panel; Merck Sharp & Dohme Corp., Pfizer Inc., Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk. S.Dagogo-jack: Consultant; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Sanofi. R.E.Pratley: Other Relationship; Bayer AG, Corcept Therapeutics, Dexcom, Inc., Hanmi Pharm. Co., Ltd., Merck & Co., Inc., Metavention, Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd. R.Frederich: Employee; Pfizer Inc., Stock/Shareholder; Bristol-Myers Squibb Company, Pfizer Inc. M.N.Essex: Employee; Pfizer Inc., Stock/Shareholder; Pfizer Inc. M.Maldonado: Employee; Merck & Co., Inc. C.Liu: Employee; Merck & Co., Inc., Stock/Shareholder; Merck & Co., Inc. J.P.Mancuso: Employee; Pfizer Inc., Stock/Shareholder; Pfizer Inc.

Funding
The VERTIS CV study and this analysis were sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
87-OR: Female Sexual Dysfunction and Type 2 Diabetes: Results from the Diabetes Prevention Program Outcomes Study (DPPOS)
Authors: GUPTA PRIYANKA , DOHERTY LINDSAY , TEMPROSA MARINELLA , WESSELLS HUNTER , POP-BUSUI RODICA , GADDE KISHORE M. , OWORA ARTHUR H. , SARMA ARUNA V. ,   DPP RESEARCH GROUP
Published: May 2022

Introduction and Objective: Female sexual dysfunction (FSD) has been reported to be more common in women with T2D. However, detailed risk profiles are lacking. We sought to determine the burden and correlates of FSD in a well characterized cohort of women with Prediabetes (PreD) and T2D enrolled in the DPPOS.
Methods: Between 1996-1999, 3,234 adults with PreD were randomized to intensive lifestyle intervention, masked metformin, or placebo in the DPP. In 2001, open-label metformin was continued for those originally randomized to it and modified lifestyle intervention offered to all. In 2016-2017, 1320 of 1464 participants completed the Female Sexual Function Index (FSFI) . 426 women were sexually active and included in the current report. FSD was defined as FSFI≥26.55. A backwards selection multivariable logistic regression model estimated odds of FSD for sociodemographic, clinical, and diabetes-related covariates significant in bivariate analysis.
Results: Overall, 185 (43%) women met the criteria for FSD. After adjustment for treatment arm, age and race, depression (defined by the Beck Depression inventory or antidepressant use) and weekly urinary incontinence were both associated with over a two-fold (OR=2.81, 95%CI=1.57, 5.02; and OR=2.14, 95%CI=1.31, 3.51) increase in odds of FSD, respectively. Women who reported hysterectomy were 1.95 times more likely (95%CI=1.07, 3.54) to report FSD. Mean study BMI was slightly protective for FSD (OR=0.93, 95%CI=0.89, 0.96) . Neither DPP treatment group nor any diabetes-related factors were associated with FSD.
Conclusions: FSD is highly prevalent in this population of women with PreD and T2D. Our findings suggest that FSD in this cohort is most strongly associated with depression. The lack of association between any measures of diabetes or glycemic control suggests that the sexual response in women is more likely to be affected by psychosocial aspects than by metabolic control or complications of diabetes.

Disclosure
P.Gupta: Consultant; Inspire . L.Doherty: None. M.Temprosa: None. H.Wessells: None. R.Pop-busui: Advisory Panel; Averitas Pharma, Inc., Boehringer Ingelheim International GmbH, Nevro Corp., Novo Nordisk, Reata Pharmaceuticals, Inc., Regenacy Pharmaceuticals, Inc. K.M.Gadde: Research Support; AstraZeneca, BioKier, Inc. A.H.Owora: None. A.V.Sarma: None. D.Research group: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (UDK048489, UDK048339, UDK048377, UDK048349, UDK048381, UDK048468, UDK048434, UDK048485, UDK048375, UDK048514, UDK048437, UDK048413, UDK048411, UDK048406, UDK048380, UDK048397, UDK048412, UDK048404, UDK048387, UDK048407, UDK048443, and UDK048400)
927-P: The Impact of Community Health Worker Interventions on A1C in People of Racial/Ethnic Minority Groups with Type 2 Diabetes: A Systematic Review and Meta-analysis
Authors: SHETTY RAJ , DECKARD AMBER , WAN WEN , NATHAN AVIVA , STAAB ERIN M. , RODRIGUEZ ALEX W. , GANDHI ASHISH , BAIG ARSHIYA A. , LAITEERAPONG NEDA 
Published: May 2022

Objective: Communities of racial/ethnic minority groups experience a higher prevalence of type 2 diabetes (T2DM) with higher rates of diabetes-related complications compared to non-Hispanic Whites. Interventions that utilize community health workers (CHW) are often successful at improving glycemic control. This analysis aimed to examine the effectiveness of CHW interventions on glycemic control in people of racial/ethnic minority groups with T2DM.
Methods: A search of electronic databases (PubMed, Scopus, CINAHL, PsycInfo) to identify articles published between 1985 and 20was conducted using broad search terms for diabetes, race/ethnicity, and disparities. To further refine articles to those focusing on CHW-based randomized controlled trials, abstracts were searched for “community workers” and “promotores.” A random effects model was used to calculate the effect of CHW interventions on hemoglobin A1c (HbA1c) with future plans to analyze effects on other cardiovascular risk factors such as body mass index, blood pressure, and cholesterol.
Results: A total of 22 RCTs were identified, involving 4996 adults (26% Black, 50% Hispanic, 11% Asian, and 11% Pacific Islander) . CHW interventions among people of racial/ethnic minority groups was associated with a 0.44% (95% confidence interval: -0.56% to -0.31%; p&lt;0.0001) reduction in HbA1c.
Conclusion: CHW interventions are an effective means to lower HbA1c among people of racial/ethnic minority groups with T2DM. This finding is important for future healthcare policies, which should work to emphasize culturally sensitive interventions for patients with T2DM while maintaining cost effectiveness through CHWs. Future research should examine the effectiveness of CHWs for diabetes prevention.

Disclosure
R.Shetty: None. A.Deckard: None. W.Wan: n/a. A.Nathan: None. E.M.Staab: None. A.W.Rodriguez: None. A.Gandhi: None. A.A.Baig: None. N.Laiteerapong: None.
937-P: Multicenter application of EFR (Endocrine Final Recommendation) Note Embedded in EMR Improves the Accuracy of Diabetes Discharge Regimen in Hospitalized Patients with Diabetes
Authors: LLOYD JACOB , ABDULWAHID TIBA , LEVIN JOEL , PINKHASOVA DIANA 
Published: May 2022

Patients with diabetes who are hospitalized often have changes in diabetes treatment regimen during hospitalization. In the ReCoDED study done at our institution, it was found that discharge instructions provided by Endocrine teams were not always accurately translated into discharge recommendations by primary teams. To address this issue, we implemented a “diabetes discharge recommendations note” (EFR Note) which clearly specifies discharge instructions for primary teams, which we embedded in the institution’s EMR in January 2019. Preliminary data evaluating the efficacy of the EFR Note at our academic center showed significantly improved accuracy in the discharge regimen.
In this study, we investigated the patient data from two other centers, specifically inner-city community hospitals, from January to December 2021. We identified 40 patients through EMR for whom an EFR Note was utilized (EFR Group) and randomly selected 40 patients from the same centers for comparison (Control Group) . There were no significant differences in baseline characteristics between the two groups (All p values &gt; 0.25)
Results: We find that the accuracy of diabetes regimens provided by primary teams at discharge was significantly higher when EFR Note was utilized, relative to control (88% vs. 60%; χ2 (1) = 6.46, p = 0.011) . The most common error was incorrect insulin type/dosing, accounting for 76% of all errors. Insulin dosing errors were similarly less prevalent in the EFR Group relative to control (8% vs. 33%; χ2 (1) = 6.33, p = 0.012) .
Conclusion: These results demonstrate that tools like EFR Note with specific instructions regarding discharge regimen can ameliorate deficiencies in discharge process. We plan to take steps to enhance awareness regarding the efficacy of EFR Note among endocrinology providers at multiple centers within our institution to facilitate a safer transition from inpatient to outpatient setting.

Disclosure
J.Lloyd: None. T.Abdulwahid: None. J.Levin: None. D.Pinkhasova: None.
94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
Authors: PIRNER MARK A. , LIN JING , LIU FENG , YAO LILI , ZETTLER MARJORIE E. , VALACER DAVID J. 
Published: May 2022

Background: RGT-075 is a small-molecule oral GLP-1 receptor agonist (GLP1RA) in clinical development. RGT-075 (15-280 mg) was well-tolerated by healthy adults in a prior phase 1 single ascending dose study. Phase 1 multiple-ascending dose study of RGT-075 in adults with type 2 diabetes (T2DM) results are presented.
Methods: A Phase 1, randomized, double-blind, placebo-controlled, inpatient study planned multiple daily doses of RGT-075 or matching placebo (6 active/2 placebo per cohort) for up to 28 days in T2DM patients (baseline HbA1c 6-10.5% and concomitant metformin &gt;500 mg/d) . An adaptive study design permitted dose and titration adjustments. Assessments included safety (primary) , PK, and exploratory efficacy changes in HbA1c, fasting plasma glucose (FPG) , continuous glucose monitoring time in range (CGM-TIR) , mixed-meal tolerance test MMTT, and body weight (BW) .
Results: Four Cohorts enrolled 36 patients (56%F/44%M; mean age 55yF/61yM) to receive ([Starting Dose]→[Titration Duration]→[Target Dose]) : Cohort 1 [60 mg][ no titration][60 mg]; Cohort 2 [30 mg][10 d][120 mg]; Cohort 3 [15 mg][20 d][180 mg]; Cohort 4 [15 mg][28 d][45 mg]. Adverse events (AEs) were reported by most subjects (100% C1 + C2; 88% C3; 83% C4; 78% pooled placebo) . Most AEs were of mild severity, drug-related for RGT-075 groups, and predominantly GI with no serious AEs or deaths. Baseline HbA1c was highly variable (7.2-9.0%) ; HbA1c mean changes from baseline ranged -0.6 to -1.2% across RGT-075 doses vs. -0.37% with placebo and correlated with FPG, CGM-TIR and MMTT results. BW mean change ranged -2.3 to -4.5 kg across RGT-075 doses vs -1.1 kg with placebo. RGT-075 plasma exposures increased as the dose levels increased.
Conclusion: RGT-075 GLP1RA oral small molecule (15-180 mg/day) up to 28 days was safe and QD dosing showed promising exploratory efficacy trends despite high baseline variability and short treatment duration.

Disclosure
M. A. Pirner: Employee; Regor Pharmaceuticals, Inc. J. Lin: None. F. Liu: Employee; Regor Pharmaceuticals Inc. L. Yao: None. M. E. Zettler: Employee; Cardinal Health, Regor Pharmaceuticals Inc. D. J. Valacer: Employee; Regor Pharmaceuticals, Inc.
960-P: Multisite Quality Improvement Initiative within the Project ECHO Diabetes Virtual Network
Authors: WANG C JASON , LEWIT EUGENE , CLARK CATHERINE , MAAHS DAVID M. , HALLER MICHAEL J. , ADDALA ANANTA , LAL RAYHAN , CUTTRISS NICOLAS , BAER LINDA G. , FIGG LAUREN , ANEZ-ZABALA CLAUDIA , SHEEHAN ELENI , WESTEN SARAH C. , DEREMER CHRISTINA E. , BERNIER ANGELINA , DONAHOO WILLIAM T. , WALKER ASHBY F. 
Published: May 2022

Poor outcomes for people with diabetes have necessitated targeted quality improvement (QI) projects to affect change. Project ECHO Diabetes is a tele-education and tele-mentoring program for community health clinics in California and Florida serving under-resourced patients with diabetes who lack routine access to specialty care. The model provided a unique opportunity to undertake a multi-site QI initiative, where 12 community clinics participated in measuring and improving quality of care. Using a modified-Delphi approach, clinic providers rated various QI measures on their validity and feasibility. A total of 18 measures were selected, and each clinic chose its own measures to track throughout the one-year initiative. The number of measures each clinic focused on ranged from 1 to 9, with a median of 3. Quarterly, clinics met remotely to report performance based on selected measures and discuss their efforts, successes, and setbacks. At the end of the QI year, clinics reported widespread improvements across structural, process, and outcome measures (Table) . Remarkable improvement ideas came from the sharing of best practices during the remote tele-ECHO clinic sessions and the changes made in the data systems used to track important measures. The Project ECHO Diabetes tele-education model has the potential to improve care for people living with diabetes in clinics serving under-resourced communities.

Disclosure
C.Wang: None. L.Figg: None. C.Anez-zabala: None. E.Sheehan: None. S.C.Westen: None. C.E.Deremer: Research Support; Pfizer-BMS Alliance, Stock/Shareholder; Portola Pharmaceuticals, Inc. A.Bernier: None. W.T.Donahoo: None. A.F.Walker: None. E.Lewit: n/a. C.Clark: None. D.M.Maahs: Advisory Panel; Abbott Diabetes, Eli Lilly and Company, Medtronic, Novo Nordisk, Sanofi, Consultant; Aditx Therapeutics, Inc., Biospex. M.J.Haller: Advisory Panel; SAB Biotherapeutics , Consultant; MannKind Corporation, Sanofi. A.Addala: None. R.Lal: Advisory Panel; Provention Bio, Inc., Consultant; Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Deep Valley Labs, Gluroo, Morgan Stanley, Tidepool. N.Cuttriss: Advisory Panel; American Diabetes Association, Board Member; American Youth Understanding Diabetes Abroad , Consultant; Cecelia Health, Leona M. and Harry B. Helmsley Charitable Trust, Med-IQ. L.G.Baer: None.

Funding
The Leona M. and Harry B. Helmsley Charitable Trust